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Purpose: To compare TG43-based and Acuros deterministic radiation transport-based calculations of
the BrachyVision treatment planning system (TPS) with corresponding Monte Carlo (MC) simulation
results in heterogeneous patient geometries, in order to validate Acuros and quantify the accuracy
improvement it marks relative to TG43.
Methods: Dosimetric comparisons in the form of isodose lines, percentage dose difference maps, and
dose volume histogram results were performed for two voxelized mathematical models resembling
an esophageal and a breast brachytherapy patient, as well as an actual breast brachytherapy patient
model. The mathematical models were converted to digital imaging and communications in medicine
(DICOM) image series for input to the TPS. The MCNP5 v.1.40 general-purpose simulation code
input files for each model were prepared using information derived from the corresponding DICOM
RT exports from the TPS.
Results: Comparisons of MC and TG43 results in all models showed significant differences, as re-
ported previously in the literature and expected from the inability of the TG43 based algorithm to
account for heterogeneities and model specific scatter conditions. A close agreement was observed
between MC and Acuros results in all models except for a limited number of points that lay in the
penumbra of perfectly shaped structures in the esophageal model, or at distances very close to the
catheters in all models.
Conclusions: Acuros marks a significant dosimetry improvement relative to TG43. The assessment
of the clinical significance of this accuracy improvement requires further work. Mathematical pa-
tient equivalent models and models prepared from actual patient CT series are useful complementary
tools in the methodology outlined in this series of works for the benchmarking of any advanced
dose calculation algorithm beyond TG43. © 2013 American Association of Physicists in Medicine.
[http://dx.doi.org/10.1118/1.4770275]
Key words: brachytherapy, 192Ir, treatment planning, Monte Carlo, Acuros
I. INTRODUCTION
A treatment planning system (TPS) for 192Ir brachytherapy
under the commercial name BrachyVision (BV, Varian Medi-
cal Systems, Inc., Palo Alto, CA), incorporating a grid based
Boltzmann equation solver (ACUROS, Transpire, Inc., Gig
Harbor, WA) as an option to account for the dosimetric ef-
fects of material heterogeneities and radiation scatter condi-
tions, received FDA approval and CE marking in 2009.1
A series of studies were designed for the independent
dosimetric verification of this deterministic radiation trans-
port based TPS approach through results comparison to
reference dose distributions obtained using Monte Carlo
simulation (MC) and experiment, as well as the evaluation
of its impact to clinical practice through results comparison
to the current standard for brachytherapy dosimetry based
on the TG43 formalism. Previous studies discussed findings
for single source dosimetry2 and a multiple source dwell
position plan employing a shielded applicator3 in bounded
geometries composed of homogeneous water. While societal
recommendations for brachytherapy dosimetry beyond the
TG43 have been published recently4 and results on its
clinical impact are becoming available without comparison
to reference dose distributions,5, 6 this last addition to the
aforementioned series reports on the benchmarking of
BV-Acuros dosimetry in heterogeneous patient geome-
tries using different voxelized anatomical computational
models.
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II. MATERIALS AND METHODS
II.A. TPS calculations
Two mathematical equation-based, stylized models and
one computed tomography (CT) image-based tomographic
model were used for the purposes of this work.
Details of the mathematical models simulating the
anatomy of the thorax of a male and the breast of a female
patient (including geometry, dimensions, and the organs or
tissues considered) have been presented in previous studies
in the literature7, 8 [see also Figs. 1(a) and 2(a)]. In order to
facilitate their import to the TPS (BrachyVision v. 8.8), each
mathematical model was voxelized through its conversion to
a series of contiguous CT images in digital imaging and com-
munications in medicine (DICOM) format. Hounsfield Units
(HUs) were assigned following the inverse of the TPS pro-
cedure for material mapping. Each material was assigned the
nominal density assumed by the TPS (see Table I) and corre-
sponding HUs were derived by applying the TPS calibration
curve. Details of the voxelized thoracic and breast mathemat-
ical models were as follows: 34 contiguous 16-bit grayscale
resolution images of 5 mm slice thickness and 1.25 mm in-
plane spatial resolution (320 mm FOV, 256 matrix); and 50
contiguous 16-bit grayscale images of 2 mm slice thickness
and 0.5859 mm in-plane spatial resolution (150 mm FOV,
256 matrix), respectively. The two CT image series were im-
ported to the TPS and volumes of interest (VOIs) were delin-
eated using the TPS-embedded tools. For the thoracic model
a brachytherapy plan resembling an esophageal treatment was
created by employing 13 dwell positions of the VS2000 192Ir
HDR source9 in a plastic catheter, with a spacing of 5 mm and
dwell times optimized to deliver a prescribed dose of 10 Gy at
a distance of 0.5 cm from the catheter longitudinal axis. For
the breast model, a planning target volume (PTV) was arbi-
trarily defined and a brachytherapy plan resembling an inter-
stitial breast treatment was created using 10 plastic catheters
and 39 VS2000 source dwell positions. A total dose of 32 Gy
was prescribed at the 100% isodose line encompassing the
PTV.
While mathematical models serve as test cases of user
defined complexity for evaluating the performance of dose
calculation algorithms, the endpoint is comparison for ac-
tual patient plans. The CT image series of an actual breast
brachytherapy patient (32 contiguous 12-bit grayscale images
of 3 mm slice thickness and 0.7168 mm in-plane spatial res-
olution, 367 mm FOV, 512 matrix) were therefore also used
in this work as an image based patient model. CT images of
the left breast of a patient were imported to the TPS and VOIs
were delineated using the TPS-embedded tools. The 14 plastic
catheters included in the image series were reconstructed and
a brachytherapy treatment plan was created using 30 VS2000
source dwell positions. A total dose of 32 Gy was prescribed
at the 100% isodose line encompassing the PTV.
The treatment plans for all three computational models
were configured using the TG43 algorithm. Dosimetric calcu-
lations for the treatment plans were performed using both the
TG43 and grid based Boltzmann solver options of the TPS (to
be referred to in the following as BV-TG43 and BV-Acuros,
respectively). In the latter case, the dose calculation and out-
put grid extent was user defined. BV-Acuros automatically
set the model region to be used as the input grid for calcu-
lations which is 10 cm larger than the output grid in each di-
mension to account for backscatter, unless the model bound-
ary is reached. Plan details, delineated VOIs, reconstructed
catheters and calculated dose matrices from all plans were ex-
ported in DICOM RT format. The spatial resolution of the RT
dose object file was 1 × 1 × 1 mm3. All subsequent data ma-
nipulation for comparisons to corresponding MC results was
conducted external to the TPS using custom made software
routines.
II.B. Monte Carlo simulation
The MCNP5 v.1.40 (Ref. 10) general purpose MC code
was used to obtain reference dose distributions for compari-
son with corresponding TPS results. Simulation models were
prepared from the CT DICOM image series of the computa-
tional models imported to the TPS, using the capability of the
employed MC code to define rectangular lattice geometries.10
Material properties were defined using a procedure iden-
tical to that of the TPS. HUs were converted to mass density
using the TPS calibration curve. Seven material types were as-
signed on a voxel-by-voxel basis using the calculated density
and the TPS table correlating density ranges to given materials
(see Table I). Material elemental compositions were then as-
signed using the same source of data employed by the TPS.11
In view of memory limitations for the patient breast model,
images were down-sampled using a box interpolation kernel
(pixel size was doubled to 1.4336 mm) and the density range
corresponding to a given material was collapsed to its nominal
density value (0.26 g cm−3, see Table I). Test MC simulations
were performed and verified that this does not affect the com-
parison between MC and BV-Acuros results. In example, the
average lung density in the CT data is 0.32 g cm−3 and per-
centage dose differences between simulations of an 192Ir point
source centered in a sphere of lung tissue with density equal
to the maximum and minimum values are under 2%. The MC
simulation input files for each model were prepared using in-
formation derived from the corresponding DICOM RT export
from the TPS (dwell positions, dwell times, total irradiation
time and air kerma strength from RT plan, catheter coordi-
nates from RT structures set, scoring grid geometry from RT
dose). The VS2000 brachytherapy source was modeled as in a
previous work2 and a separate simulation was performed for
each dwell position to preclude intersource attenuation that
does not occur in clinical practice using remote afterloaders.
Results were combined after weighting by the corresponding
ratio of dwell time to the total irradiation time. In contrast to
source dwell positions, the direction of the longitudinal source
axis in them is not information available in RT plan and it was
therefore deduced from the coordinates of two catheter points
closely encompassing each dwell position.
Simulations were performed using the MCPLIB04
(Ref. 12) cross section data library and the 192Ir photon spec-
trum from Glasgow and Dillman13 considering only the pene-
trating part (i.e., photon energies greater than 11.3 keV). The
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FIG. 1. (a) The central image of the voxelized mathematical thoracic model including lungs, spine, spinal cord, trachea, and sternum structures. BV-TG43,
BV-ACUROS, and MC dose calculation results for the same esophagus brachytherapy plan are presented in the form of percentage isodose lines within the
extent of the dose calculation grid. (b) A colormap representation of the spatial distribution of percentage differences between BV-TG43 and MC results
( DBV-TG43
DMC
− 1) on the plane presented in (a). (c) A colormap representation of the spatial distribution of percentage differences between BV-Acuros and MC
results ( DBV-ACUROS
DMC
− 1) on the plane presented in (a). (d) Cumulative DVH results for the lungs, spinal cord, and trachea OARs derived from the 3D dose
distributions calculated using BV-TG43, BV-ACUROS, and MC.
relative uncertainty associated with cross section data is 2%.14
Although contemporary data available for the 192Ir photon
spectrum are expected to be of improved accuracy relative to
that in Glasgow and Dillman,13 the latter were also used for
the calculation of the VS2000 source TG43 dosimetric pa-
rameters employed by the TPS.9 Besides, the contribution of
uncertainty in the photon energy spectrum is negligible, and
the relative uncertainty in photon yields cancels out for dose
ratios such as those presented in this work.14
With the clinical availability of dose calculation methods
beyond the TG43 assumptions, dose can be specified either
in tissue or in water and the question of dose specification
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FIG. 2. (a) The central image of the voxelized mathematical breast model with BV-TG43, BV-ACUROS, and MC dose calculation results for the same breast
brachytherapy plan presented in the form of percentage isodose lines within the extent of the dose calculation grid. (b) A colormap representation of the spatial
distribution of percentage differences between BV-TG43 and MC results ( DBV-TG43
DMC
− 1) on the plane presented in (a). (c) A colormap representation of the
spatial distribution of percentage differences between BV-Acuros and MC results ( DBV-ACUROS
DMC
− 1) on the plane presented in (a). (d) Cumulative DVH results
for the PTV derived from the 3D dose distributions calculated using BV-TG43, BV-ACUROS and MC. (e) Same as (d) for the skin and lung OARs.
medium has been recently linked to microdosimetric consid-
erations of correlating the dose distribution to biologically
relevant targets.4 Since the TPS studied herein reports water
collision kerma (in water in the case of BV-TG43 or in the
heterogeneous model geometry in the case of BV-Acuros),
secondary electron transport was not simulated in this work
and water collision kerma was scored using the *FMESH4
tally with a resolution of 1 × 1 × 1 mm3 superimposed
over the simulated model geometry. The specific tally calcu-
lates the track length estimate of the energy fluence averaged
over a mesh cell in units of MeV cm−2 per starting photon,
which was converted to MeV g−1 per starting photon using
water mass energy absorption coefficients taken from NIST
(Ref. 15) in the input files along with a dose energy and func-
tion card.
A different number of photon histories per source dwell
position were simulated for each computational model. The
estimated relative error at the 1σ level, as obtained using error
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TABLE I. Materials included in the computational models of this work, along
with the range of mass densities correlated by the TPS to these materials
according to the BrachyVision-Acuros algorithm reference guide.
Density (g cm−3)
Material Low Nominal High
Air (STP) 0.001 0.001205 0.1306
Lung 0.1306 0.26 0.605
Adipose tissue 0.605 0.92 0.985
Muscle, skeletal 0.985 1.05 1.075
Watera 1
Cartilage 1.075 1.10 1.475
Bone 1.475 1.85 2.2275
aComparison of BV-Acuros results for an 192Ir point source centered in a homoge-
neous, 15 cm radius, sphere model of HU = 0 with corresponding MC simulation
results in the same model comprising of either water or muscle tissue, suggests
that the TPS assumes water material when HU is equal to zero (i.e., density equals
unity).
propagation on the corresponding relative error values calcu-
lated by the MC code for each dwell position, is under 2% at
all points in the mathematical esophageal model [1% in the
region encompassed by the 3% isodose line, see Fig. 1(a)],
under 1% at all points in the mathematical breast model [see
Fig. 2(a)], and under 3% at all points in the real breast patient
model [1% and 2% at short and intermediate distances from
the PTV, respectively, see Fig. 3(a)]. Simulation results were
converted to absorbed dose using the air kerma strength per
starting photon value for the VS2000 source,2 along with the
information of source air kerma strength and total irradiation
time of each treatment plan.
III. RESULTS
III.A. Dosimetry comparison in the voxelized
mathematical models
Figure 1 presents results of the comparison between BV-
TG43, BV-ACUROS, and MC dose calculations for the same
esophagus brachytherapy plan in the voxelized mathematical
thoracic model. In Fig. 1(a) results are presented in the form
of percentage isodose lines superimposed on the central axial
image of the model. In this figure, an overall good agreement
can be seen for the relatively higher isodose lines lying close
to the catheter. As distance from the catheter increases, how-
ever, BV-TG43 results deviate from the other two datasets as
expected7, 8 due to the difference in the scatter and attenua-
tion properties of the materials comprising the model geome-
try relative to water which is assumed in the calculation of the
TG43 dosimetry data for the VS2000 source.9
Percentage differences between BV-TG43 and MC results
are quantified in Fig. 1(b) on a pixel by pixel basis, and the
former can be seen to overestimate the dose to the spinal cord
by up to 20% and underestimate the dose to the sternum and
the trachea by up to 15%. Percentage differences in the lungs
are position dependent, reaching ±20%. In Fig. 1(c), where
percentage differences between BV-Acuros and MC results
are presented on a pixel by pixel basis on the same plane as in
Fig. 1(b), an excellent agreement (±2%) can be seen for the
majority of the presented points. In a limited number of points
lying close to the directions defined by primary photon rays
tangential to the spine and the trachea structures, however,
BV-ACUROS results differ by up to 6% from corresponding
MC results. This could be attributed to the ineffectiveness of
the ray tracing algorithm employed by the TPS (Ref. 2) man-
ifested only under extreme conditions such as the penumbra
of a shield3 or the ideally shaped spine and trachea structures
of the model, as well as any difference in the discretization
errors inherently involved in MC and BV-Acuros results.
Besides comparison in two dimensions, BV-TG43, BV-
ACUROS, and MC results are also compared in the form
of cumulative dose volume histograms (DVH) in Fig. 1(d).
Agreement between all three datasets can be observed only
for the case of the lung. This is in accordance with findings
presented in Fig. 1(b) which suggest that the TG43 based
dosimetric algorithm overestimates the delivered dose at the
posterior part of lungs while underestimating it at the ante-
rior part, and therefore a major fraction of these differences
cancels out in terms of DVH values. Regarding the spinal
cord and the trachea, it can be seen that the BV-TG43 calcu-
lated cumulative DVH is shifted toward higher and lower dose
levels, respectively, relative to corresponding MC results, in
agreement with results of Fig. 1(b). An excellent agreement
between the BV-ACUROS and MC based calculated DVH re-
sults can be observed for all the organs at risk (OARs) pre-
sented in Fig. 1(d).
Figure 2(a) presents the comparison of BV-TG43, BV-
ACUROS, and MC results for the same treatment plan in the
voxelized mathematical breast model, in the form of percent-
age isodose lines superimposed on the central axial image of
the model. While a good agreement can be observed between
BV-ACUROS and MC results, TG43 results present an in-
creasing dose overestimation relative to the other two datasets
with increasing distance from the PTV. This dose overestima-
tion is further quantified in Fig. 2(b) where percentage differ-
ences between BV-TG43 and MC results are presented on a
pixel by pixel basis. In this figure, it can be seen that due to
the combined effect of the lung heterogeneity and the finite
patient dimensions, BV-TG43 significantly overestimates the
dose distribution in agreement with previous findings in the
literature.8 Apart from this effect, a BV-TG43 dose underes-
timation greater than 25% is observed at points lying within
the volume of the catheters (these points were not excluded
from either dataset). A significant dose underestimation rel-
ative to MC results is also observed at points close to the
sources probably due to the extrapolation algorithm employed
by the TPS for points outside its input data grid. A slight dose
underestimation is also observed in the positive x side of the
PTV that is attributed to the different source drive wire length
assumed in the simulations of this work2 (1 mm) and the sim-
ulations for the data used as input to the TPS for TG43 based
dose calculations9 (15 cm).16
In Fig. 2(c), where percentage differences between BV-
Acuros and MC results are presented on a pixel by pixel basis
on the same plane as in Fig. 2(b), it can be seen that BV-
Acuros succeeds in accounting for the lung heterogeneity and
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FIG. 3. (a) The central image of the breast patient computational model with BV-TG43, BV-ACUROS, and MC dose calculation results for the same breast
brachytherapy plan presented in the form of percentage isodose lines within the extent of the dose calculation grid. (b) A colormap representation of the spatial
distribution of percentage differences between BV-TG43 and MC results ( DBV-TG43
DMC
− 1) on the plane presented in (a). (c) A colormap representation of the
spatial distribution of percentage differences between BV-Acuros and MC results ( DBV-ACUROS
DMC
− 1) on the plane presented in (a). (d) Cumulative DVH results
for the PTV derived from the 3D dose distributions calculated using BV-TG43, BV-ACUROS, and MC. (e) Same as (d) for the skin, lung, and heart OARs.
the geometry specific scatter conditions since agreement with
MC results within ±1% is observed for the majority of points.
Significant differences are only observed within the catheters
(these points were not excluded from either dataset) as well as
points close to the sources, probably, due to an inefficiency of
the BV-Acuros ray tracing algorithm to predict the steep dose
gradient close to the sources.
Cumulative DVH results derived from the dose distribu-
tions calculated using BV-TG43, BV-ACUROS, and MC for
the same plan in the same breast model are presented in
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Fig. 2(d). For the PTV, good agreement is observed for low
percentage dose values; PTV coverage is comparable for all
three datasets, and the same applies for the conformity in-
dex (defined as the ratio of reference isodose volume to tar-
get volume and found equal to: 0.960, 0.957, and 0.956 for
MC, BV-TG43, and BV-Acuros, respectively). Agreement be-
tween the three datasets deteriorates as percentage dose in-
creases, and significant differences between DVH results are
observed at increased percentage dose levels that are also
reflected on corresponding dose homogeneity index results
[defined as (V100%–V150%)/V100% and found equal to: 0.642,
0.680, and 0.747 for MC, BV-TG43, and BV-Acuros, respec-
tively]. These differences come from differences between the
corresponding dose distributions discussed above at points in-
side or close to the catheters, and are therefore artificial to
a large degree in view of the large fraction of the PTV cor-
responding to points inside the catheters for the small PTV
volume studied (7.25 cm3). For the lung and the skin OARs,
BV-TG43 results in Fig. 2(d) can be seen to overestimate the
DVHs relative to corresponding BV-Acuros and MC results
which are in close agreement.
III.B. Dosimetry comparison in the patient model
Figure 3(a) presents the comparison of BV-TG43, BV-
ACUROS, and MC results for the same treatment plan in the
breast patient computational model, in the form of percent-
age isodose lines superimposed on the central axial image
of the model. Similar to results in the voxelized mathemati-
cal breast model, a close agreement is observed between all
three datasets close to the PTV. As distance from the PTV in-
creases, BV-TG43 results overestimate the dose distribution.
This dose overestimation is more evidently shown in Fig. 3(b)
where percentage dose differences up to 10% in the lung and
20% in the breast skin are observed between of BV-TG43 and
MC results. In accordance with findings discussed above for
the mathematical breast model, a BV-TG43 dose underesti-
mation is observed within or close to the catheters, as well as
in the drive wire side of the PTV.
In Fig. 3(c), where percentage differences between BV-
Acuros and MC results are presented on a pixel by pixel basis
on the same plane as in Fig. 2(b), it can be seen that BV-
Acuros provides dose calculation accuracy comparable to MC
since agreement within ±2% is observed for the majority of
points. As with the case of the mathematical breast model,
significant differences are only observed within or close to the
catheters. In contrast to results in Fig. 2(d), however, these dif-
ferences do not significantly affect PTV DVH results due to
the relatively larger PTV volume (45.86 cm3). This is shown
in Fig. 3(d) where cumulative DVH results derived from the
dose distributions calculated using BV-TG43, BV-ACUROS,
and MC are in close agreement for the PTV, with a minor un-
derestimation observed for BV-Acuros at relatively increased
percentage dose values. PTV coverage is comparable for all
three datasets, and the same applies for the conformity index
(0.901, 0.900, and 0.901 for MC, BV-TG43, and BV-Acuros,
respectively) and the dose homogeneity index (0.673, 0.669,
0.676 for MC, BV-TG43, and BV-Acuros, respectively). BV-
Acuros and MC DVH results for the OARs in Fig. 3(d) are in
close agreement, with a slight overestimation discernible for
BV-TG43 results.
IV. DISCUSSION
Ample literature exists that presents data similar to the
comparison between MC and BV-TG43 results performed in
this work to quantify the accuracy improvement achieved by
BV-Acuros.
In an early study using TLD and film measurements in
phantoms as well as in vivo, Mangold et al.17 reported an av-
erage dose overestimation of 14% at the tissue-air interface in
an experimental quality control study of PDR 192Ir interstitial
breast brachytherapy performed using TG43-based treatment
planning.
Anagnostopoulos et al.7 and Pantelis et al.8 compared
MCNPX simulation results to TG43-equivalent dose calcu-
lations in the original studies introducing the mathematical
computational models resembling an esophageal and an in-
terstitial breast brachytherapy patient that were also used in
this work. Their results are in agreement with the compar-
ison of MC and BV-TG43 presented in this work besides
methodological differences including the use of a different
192Ir source and plan, tissue elemental compositions adopted
from different sources [ICRU Report 44 (Ref. 18) versus
ICRP Report 23 (Ref. 11) in this work], different cross section
libraries (MCPLIB02 versus MCPLIB04 used in this work),
the fact that tissue kerma in tissue was scored in the original
studies, and the voxelization of the mathematical computa-
tional models in this work.
Within the context of introducing an analytical scatter
correction technique as an alternative to TG43 based cal-
culations, Poon and Verhaegen19 compared PTRAN CT
MC (Ref. 20) simulations in the CT-based geometries of
18 multicatheter breast brachytherapy patients to TG43
based dose calculations, taking into account four tissue types
(lung, adipose, soft tissue, and rib bone) with elemental
compositions according to the ICRU Report 44.18 Their
results, presented in the form of isodose lines and DVHs
for an indicative patient and tabulated DVH statistics for the
patient cohort, are compatible with corresponding results of
this work showing a TG43 dose overestimation of skin, heart,
and lung. On average, all presented DVH statistics were over-
estimated by TG43 (i.e., 5%, 2%, and 5% for skin, heart, and
lung D0.1cc, respectively) with considerable variation between
patients.19
In a subsequent study21 proposing a CT-based analytical
dose calculation method for HDR 192Ir brachytherapy, the
same authors compared PTRAN CT MC (Ref. 20) simula-
tions and TG43 calculations in the CT-based geometry of an
esophageal brachytherapy patient and reported results simi-
lar to those of Anagnostopoulos et al.7 and this work. The
same comparison in the CT-based geometry of an intracavi-
tary breast brachytherapy case with a balloon applicator filled
with iodine contrast solution, showed that TG43 overesti-
mated dose to the target, skin, and ipsilateral lung by more
than 5%.
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The comprehensive experimental study of Raffi et al.22
also reported a TG43-based TPS skin dose overestimation in
intracavitary breast brachytherapy employing contrast filled
balloon applicators. While TLD measurements, MCNP5 sim-
ulation, and TG43-based treatment planning were found in
excellent agreement in phantoms simulating TPS assump-
tions, the TG43-based results were shown to overestimate exit
skin dose to water 9%–15% for phantom setups simulating
treatment conditions and by 16%, on average, for a group of
59 patients, with a considerable variation between fractions
and patients (TLD and TPS difference ranged from −13% to
47%).
The only study reporting findings that are not compatible,
at least qualitatively, with the results of the comparison be-
tween MC and BV-TG43 presented in this work is that of
Mille et al.23 This study was based on MCNPX simulations in
a virtual balloon breast brachytherapy patient prepared from
voxelizing the RPI-adult female computational model.24 A
comparison between MCNPX results in the inhomogeneous
model and the same model with all the tissues set to water
was included for a point 192Ir source centered in a balloon
modeled as a sphere of water. The latter results are equiva-
lent to TG43 based dose calculations taking, however, into
account the finite patient dimensions and, therefore, skin dose
was found comparable in the inhomogeneous and water com-
putational models.23 Isodose line comparison, average dose
results, and DVH results for the ipsilateral lung, however, all
suggest that the dose to the lung was found greater in the inho-
mogeneous model (i.e., 640 cGy average organ dose relative
to 593 cGy in the water model) in contrast to results presented
in this and previous studies.8, 19, 21 Although some influence
from the scatter conditions configured by the finite patient di-
mensions to the dose to the lung cannot be ruled out, it is not
clear whether these findings are justified by the source-organ
geometry and other assumptions in the study of Mille et al.,23
or associated with the methods used for tallying and the tally
conversion to dose.
The results discussed above support that, on average, TG43
based dosimetry overestimates dose to the skin, heart, and
lung OARs with a percentage dose difference between TG43
and reference dose distributions that depend more on patient
and treatment specific geometric parameters than on the de-
tails of the methodology used to calculate the reference dose
distributions.
Besides differences in their aim and methods, the studies
discussed above seek to quantify the inaccuracies of TG43
based dosimetry either experimentally or through the use of
computational models that are as close to reality as possible
with regard to geometry, tissue density, and tissue elemental
composition. This work is fundamentally different, focusing
to the validation of BV-Acuros dosimetry. Since BV-Acuros
was the first dose calculation engine beyond TG43 that is clin-
ically available, meticulous work was done to configure MC
simulations so that their input is as close as possible to the
input of BV-Acuros and ensure there is no bias in the compar-
ison of their outputs. Whether the computational models in-
cluded in this input are the most realistic that can be achieved
or representative of individual or average patients is beyond
the scope of this work. In this context, results of this work
show that, when provided with the same input, BV-Acuros
achieves accuracy comparable to MC except for a limited
number of points lying in the penumbra of perfectly shaped
structures that can only be met in mathematical computational
models and points within the catheters or close to the source
that are not clinically significant.
V. CONCLUSIONS
Dosimetric calculations were performed in voxelized
anatomical computational models of heterogeneous patient
geometries using Monte Carlo simulation as well as the
TG43 and Acuros grid based Boltzmann solver options of the
BrachyVision treatment planning system (abbreviated as BV-
TG43 and BV-Acuros, respectively, in this work). Compari-
son of BV-TG43 and Monte Carlo results verified the short-
comings of the, otherwise robust and computationally nonin-
tensive, TG43 formalism.7, 8, 17, 19, 21, 22 While the BV-Acuros
dose calculation engine is not currently used for optimiza-
tion and dose prescription, it was found to correctly account
for heterogeneities and patient specific scatter conditions pro-
viding accuracy comparable to Monte Carlo simulation. The
clinical significance of the improved accuracy offered by BV-
Acuros remains to be evaluated in studies of site specific treat-
ment plan cohorts.
Mathematically, patient equivalent models and models pre-
pared from actual patient CT series proved complementary
tools for testing the dosimetric accuracy of BV-Acuros; the
former comprising an unambiguous means to define a test
case for comparisons without bias from organ geometry and
material properties delineation and the latter serving as an in-
tegral test of conditions met in actual clinical practice.
This work, combined with the previous two in the series,2, 3
forms a protocol of tests and methods useful for a thorough
benchmarking of any advanced brachytherapy treatment plan-
ning system beyond TG43.
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